Switch theme
Sign up to access all valuation multiples
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
2015
188
LTM Revenue $192M
LTM EBITDA -$4.5M
$675M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Avadel Pharmaceuticals has a last 12-month revenue of $192M and a last 12-month EBITDA of -$4.5M.
In the most recent fiscal year, Avadel Pharmaceuticals achieved revenue of $169M and an EBITDA of -$35.6M.
Avadel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Avadel Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $28.0M | $169M | XXX | XXX | XXX |
| Gross Profit | n/a | $27.1M | XXX | XXX | XXX |
| Gross Margin | NaN% | 16% | XXX | XXX | XXX |
| EBITDA | -$149M | -$35.6M | XXX | XXX | XXX |
| EBITDA Margin | -533% | -21% | XXX | XXX | XXX |
| Net Profit | -$137M | -$160M | XXX | XXX | XXX |
| Net Margin | -492% | -95% | XXX | XXX | XXX |
| Net Debt | $55.3M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Avadel Pharmaceuticals's stock price is $8.
Avadel Pharmaceuticals has current market cap of $747M, and EV of $675M.
See Avadel Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $675M | $747M | XXX | XXX | XXX | XXX | $-0.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Avadel Pharmaceuticals has market cap of $747M and EV of $675M.
Avadel Pharmaceuticals's trades at 3.5x LTM EV/Revenue multiple, and -151.4x LTM EBITDA.
Analysts estimate Avadel Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Avadel Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $675M | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | -19.0x | XXX | XXX | XXX |
| P/E | -15.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAvadel Pharmaceuticals's NTM/LTM revenue growth is 42%
Avadel Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Avadel Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Avadel Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Avadel Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 505% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -76% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 116% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avadel Pharmaceuticals acquired XXX companies to date.
Last acquisition by Avadel Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Avadel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Avadel Pharmaceuticals founded? | Avadel Pharmaceuticals was founded in 2015. |
| Where is Avadel Pharmaceuticals headquartered? | Avadel Pharmaceuticals is headquartered in United States of America. |
| How many employees does Avadel Pharmaceuticals have? | As of today, Avadel Pharmaceuticals has 188 employees. |
| Who is the CEO of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's CEO is Mr. Gregory J. Divis. |
| Is Avadel Pharmaceuticals publicy listed? | Yes, Avadel Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Avadel Pharmaceuticals? | Avadel Pharmaceuticals trades under AVDL ticker. |
| When did Avadel Pharmaceuticals go public? | Avadel Pharmaceuticals went public in 1996. |
| Who are competitors of Avadel Pharmaceuticals? | Similar companies to Avadel Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's current market cap is $747M |
| What is the current revenue of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's last 12-month revenue is $192M. |
| What is the current EBITDA of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's last 12-month EBITDA is -$4.5M. |
| What is the current EV/Revenue multiple of Avadel Pharmaceuticals? | Current revenue multiple of Avadel Pharmaceuticals is 3.5x. |
| What is the current EV/EBITDA multiple of Avadel Pharmaceuticals? | Current EBITDA multiple of Avadel Pharmaceuticals is -151.4x. |
| What is the current revenue growth of Avadel Pharmaceuticals? | Avadel Pharmaceuticals revenue growth between 2023 and 2024 was 505%. |
| Is Avadel Pharmaceuticals profitable? | Yes, Avadel Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
